Following U.S. Stocks were among the “Top Gainers” during Friday’s trade: Aoxing Pharmaceutical Company, (NYSEMKT:AXN), DURECT, (NASDAQ:DRRX), Direxion Shares Exchange Traded Fund, (NYSEARCA:JDST), RXi Pharmaceuticals, (NASDAQ:RXII)

Their insights are depicted underneath:

Aoxing Pharmaceutical Company, Inc (NYSEMKT:AXN)’s shares picked up 33.04%, and closed at $1.49.

According to Accesswire, Aoxing Pharmaceutical Corporation, Inc. (AXN), a specialty pharmaceutical corporation focusing on research, development, manufacturing, and distribution of narcotic, pain-administration, and addiction treatment pharmaceuticals, declared its financial and operational results for the quarter ended December 31, 2014.

Second Quarter 2015 Highlights:

• Proceeds in the second quarter raised 85% year over year to $6.4 million while cost of sales reduced 20% year over year to $1.6 million. Gross profit for the second quarter was $4.8 million, representing a 75% gross margin, and an raise of 233% as contrast to the same quarter last year.
• Net profit for the second quarter was $0.6 million instead of a net loss of $1.9 million for the same quarter last year.
• Net cash generated from operating activities for the six months ended December 31, 2014 was $3.4 million contrast to the use of $2.8 million cash in operations for the period ended December 31, 2013.
• Basic and diluted revenue per ordinary share were both $0.01 for the second quarter as contrast to net loss of ($0.04) per basic and diluted share for the same quarter last year.

Aoxing Pharmaceutical Corporation, Inc. (AXN), is a US incorporated specialty pharmaceutical corporation with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-administration products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines.

DURECT Corporation (NASDAQ:DRRX), raised 22.39%, and closed at $1.64.

According to PRNewswire, DURECT Corporation (DRRX) declared financial results for the three months ended December 31, 2014. Total proceeds were $4.3 million for the three months ended December 31, 2014 and for the three months ended December 31, 2013. Net loss was $5.9 million for the three months ended December 31, 2014 as contrast to a net loss of $5.1 million for the same period in 2013.

Total proceeds were $19.4 million and net loss was $22.1 million for the year ended December 31, 2014, contrast to total proceeds of $15.3 million and net loss of $21.5 million for the year ended December 31, 2013.

At December 31, 2014, we had cash and investments of $34.9 million, contrast to cash and investments of $24.4 million at December 31, 2013. At December 31, 2014, we had $19.8 million in long term debt.

DURECT is a specialty pharmaceuticals corporation with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain administration, acute organ injury and metabolic diseases.

Direxion Shares Exchange Traded Fund Trust (NYSEARCA:JDST), enhanced 22.19%, and closed at $12.50.

According to ETFtrends, The sudden drop in gold and miners may have caught traders off guard as asset flows revealed that leveraged and inverse gold ETF traders have been dumping bearish bets over the past month, according to Direxion data. Specifically, the Direxion Daily Gold Miners Bear 3X Shares (DUST) practiced $779,000 in outflows and Direxion Daily Junior Gold Miners Index Bear 3X Shares (JDST) saw $951,000 in outflows over the past 30-days. However, the two leveraged inverse trades were among the best performing ETFs Friday, with DUST jumping 22.2% and JDST surging 21.9%.

The investment seeks daily investment results, before fees and expenses, of 300% of the inverse (or opposite) of the performance of the Market VectorsTM Global Junior Gold Miners Index. The fund creates short positions by investing at least 80% of its assets in: futures contracts; options on securities, indices and futures contracts; equity caps, floors and collars; swap contracts; forward contracts; short positions; reverse repurchase contracts; exchange-traded funds; and other financial instruments that, in combination, provide inverse leveraged and unleveraged exposure to the Market VectorsTM Global Junior Gold Miners Index.

RXi Pharmaceuticals Corp (NASDAQ:RXII), skyrocketed 20.97%, and closed at $1.50. The company has the market capitalization of $31.70M. On the other hand the stock’s volatility for the week is 10.37%, and for the month is 7.80%. The stock price to book value is $9.38, however price to sale value is $368.55. Analyst’s mean recommendation regarding this stock is 2.00. (where 1=Buy, 5=Sale).

RXi Pharmaceuticals Corporation, a biotechnology corporation, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform.